| Abstrakt: |
A clinical trial, NCT06506396, is currently underway in Italy to evaluate the physical abilities, quality of life, and symptoms of patients undergoing hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor (CAR) T-cell therapy. These treatments are effective for blood cancers but can have side effects such as muscle weakness and fatigue. The study aims to identify the rehabilitation needs of these patients in order to minimize these side effects and improve their overall well-being. The trial is expected to be completed by May 2025 and will provide valuable insights for improving the care of patients undergoing these advanced treatments. [Extracted from the article] |
